Clearline Capital’s Wave Life Sciences WVE Stock Holding History

Clearline Capital’s Portfolio WVE Stock Details WVE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-49,569	Closed	-$397K	–	88
2019 Q4	$397K	Buy	+49,569	New	+$1.22M	0.17%	50

Other funds holding WVE

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Clearline Capital's WVE Position: Q1 2020 in Review

Clearline Capital sold out of Wave Life Sciences (WVE) in Q1 2020, closing a stake of 49,569 shares — an estimated $397K sold.

Clearline Capital first reported a position in WVE in Q4 2019 and held it in 1 quarter. The position peaked at $397K in Q4 2019. 78 funds tracked by Wall St. Rank hold WVE as of Q1 2020.

Clearline Capital reported no remaining Wave Life Sciences position as of Q1 2020 after selling out during the quarter.
Clearline Capital sold 49,569 Wave Life Sciences shares in Q1 2020, an estimated $397K.
Clearline Capital first reported a position in Wave Life Sciences in Q4 2019 and held it in 1 quarter.
Clearline Capital's Wave Life Sciences position peaked at $397K in Q4 2019.
78 funds tracked by Wall St. Rank held Wave Life Sciences as of Q1 2020.

Based on Clearline Capital's 13F filing for Q1 2020, filed 15 May 2020.